TY - JOUR
T1 - New strategies in bladder cancer
T2 - A second coming for immunotherapy
AU - Ghasemzadeh, Ali
AU - Bivalacqua, Trinity J.
AU - Hahn, Noah M.
AU - Drake, Charles G.
N1 - Funding Information:
A. Ghasemzadeh was supported by the NIH under award number T32GM007309. C.G. Drake is supported by the NIH under award number R01CA127153, the Patrick C. Walsh Prostate Cancer Research Fund, the One-in-Six Foundation, the Prostate Cancer Foundation, and the Melanoma Research Alliance.
Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/2/15
Y1 - 2016/2/15
N2 - Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinumbased chemotherapy, which has been the standard-ofcare in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development.
AB - Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinumbased chemotherapy, which has been the standard-ofcare in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development.
UR - http://www.scopus.com/inward/record.url?scp=84964322531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964322531&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-1135
DO - 10.1158/1078-0432.CCR-15-1135
M3 - Article
C2 - 26683632
AN - SCOPUS:84964322531
SN - 1078-0432
VL - 22
SP - 793
EP - 801
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -